BioSpace News Archive

Pillar Biosciences, today announced that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will participate in investor meetings at the 2022 Wells Fargo Healthcare Conference at the Encore Boston Harbor in Everett, MA on September 7-9, 2022.

IAVI, a nonprofit scientific research organization, announces that volunteers at the PREVAIL clinical trial site at Redemption Hospital (RH1) in Monrovia, Liberia, have been vaccinated with IAVI’s novel vaccine candidate against Lassa fever virus (LASV) in a Phase I clinical trial, named IAVI C102, supported by the Coalition for Epidemic Preparedness Innovations (CEPI).

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000, an investigational therapy for the treatment of erectile dysfunction (“ED”).

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Wednesday, September 14, 2022, at 12:20 p.m. ET.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary preclinical data from mouse and non-human primate studies of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.

OpGen, Inc. announced that it has received written notification from the Listing Qualification Department of The NASDAQ Stock Market granting OpGen’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550.

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

argenx announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.